Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2022-05-12 Major Shareholding Noti…
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2022-05-12 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-12 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2022, by TScan Therapeutics, Inc. It announces the issuance of a press release reporting financial results for the quarter ended March 31, 2022. The document explicitly states that the press release is furnished as an exhibit and is not filed as part of the report. The text does not contain the actual financial results or detailed financial statements but rather references the press release. The document length is 3786 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the rules, a short document announcing the release of financial results without containing the results itself should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER).
2022-05-09 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It includes information about the upcoming annual meeting, voting instructions, and proposals such as election of directors and ratification of auditors. The document is titled 'Definitive Additional Materials' related to the proxy statement for the annual meeting. It does not contain the full proxy statement itself but additional materials related to it. According to the filing definitions, proxy solicitation and information statements are classified under PSI. The document length is 3263 characters, which is relatively short and consistent with additional proxy materials rather than a full annual report or other detailed filings. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2022-04-21 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.